Eyebrows Raised As Roche Inks Cardiovascular Pact With Alnylam

Bags Rights To Hypertension Therapy Zilebesiran

The Swiss major is so keen to get access to Alnylam’s RNAi therapeutic targeting angiotensinogen that it is paying $310m upfront having only seen Phase I data. Some analysts are unsure if it is a good idea.

Roche
• Source: Roche

Roche Holding AG has taken the surprising step of jumping into the cardiovascular space and teamed up with Alnylam Pharmaceuticals Inc. to co-develop and co-commercialize zilebesiran, the RNA interference (RNAi) specialist's keenly-watched twice-yearly injection for hypertension.

The Swiss giant is paying $310m upfront while Alnylam is eligible to receive additional "substantial" near-term and development milestone payments...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiovascular

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

 

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

More from Therapy Areas

Sumitomo Parkinson’s Filing A Pivotal Moment For Japan’s iPSC Ambitions

 
• By 

Sumitomo Pharma's iPSC therapy for Parkinson's has been filed for approval in Japan after showing safety and efficacy in a Phase I/II trial and may become one of the first such therapies to reach the market in the country, which has invested heavily in the modality.

HHS mRNA Vaccine Wind-Down Has Limited Impact (And One Contract Isn’t Even mRNA)

 

The news will have a big impact on pandemic preparedness but less immediate financial impact. Tiba Biotech was even “caught off guard” by its inclusion in the department’s culling of mRNA vaccine projects under BARDA, as its project was neither a vaccine nor mRNA-based.

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

 

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.